pending drug product application who knowingly uses the services of Mr. Marcus in any capacity during his period of debarment, will be subject to civil money penalties. If Mr. Marcus, during his period of debarment, provides services in any capacity to a person with an approved or pending drug product application, he will be subject to civil money penalties. In addition, FDA will not accept or review any abbreviated new drug applications submitted by or with the assistance of Mr. Marcus during his period of debarment.

Any application by Mr. Marcus for termination of debarment under section 306(d)(4) of the act should be identified with Docket No. 99N–2674 and sent to the Dockets Management Branch (address above). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.


Janet Woodcock,
Director, Center for Drug Evaluation and Research.

[FR Doc. 00–25088 Filed 9–28–00; 8:45 am]
BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 94N–0424]

Mohammad Uddin; Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) permanently debarring Mr. Mohammad Uddin from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Uddin was convicted of a felony under Federal law for conduct relating to the regulation of a drug product.

The proposed debarment order provides for a hearing on this finding, under section 306(a)(2)(B) of the act, if Mr. Uddin requests it. The proposed debarment order also provides for a hearing for a period of 30 days after publication of this notice, during which time Mr. Uddin shall have the opportunity to contest the proposed debarment order.

The period of debarment, if finally imposed, will be permanent.


Janet Woodcock,
Director, Center for Drug Evaluation and Research.

[FR Doc. 00–25086 Filed 9–28–00; 8:45 am]
BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 98F–0290]

The Dow Chemical Co.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 8B4586) proposing that the food additive regulations be amended to provide for the safe use of certain olefin basic copolymers, derived from ethylene and alpha monomers with eight or fewer carbon atoms, as articles or as components of articles intended for use in contact with food.


SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of May 7, 1998 (63 FR 25212), FDA announced that a food additive petition (FAP 8B4586) had been filed by the Dow Chemical Co., 2030 Dow Center, Midland, MI 48674. The petition proposed to amend the food additive regulations to provide for the safe use of certain olefin basic copolymers, derived from ethylene and alpha monomers with eight or fewer carbon atoms, as articles or as components of articles intended for use in contact with food.